Disease Landscape and Forecast Insights

Clarivate Epidemiology’s coverage of acute heart failure (AHF) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the hospitalization rate of AHF…

Clarivate Epidemiology’s coverage of acute heart failure (AHF) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the hospitalization rate of AHF…

Clarivate Epidemiology’s coverage of coronary heart disease (CHD) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and…

NASH has the potential to be a large and lucrative therapy market owing to the prevalence of the disease and the lack of approved agents. Patients with NASH are at risk of liver fibrosis,…

Atherosclerotic cardiovascular disease (ASCVD) broadly covers coronary artery disease, including acute coronary syndrome, a history of myocardial infarction, stable or unstable angina, as well as…

Clarivate Epidemiology’s coverage of acute coronary syndrome comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and…

Clarivate Epidemiology’s coverage of acute coronary syndrome comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and…

Clarivate Epidemiology’s coverage of acute coronary syndrome comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and…

Clarivate Epidemiology’s coverage of acute coronary syndrome comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and…

The pharmaceutical market for nonalcoholic steatohepatitis (NASH), a severe form of nonalcoholic fatty liver disease (NAFLD), has the potential to become lucrative owing to the current lack of…

Primary biliary cholangitis (PBC) is a rare autoimmune liver disease characterized by inflammation, progressive damage, and, ultimately, destruction of the interlobular bile ducts; this process is…

Nonalcoholic steatohepatitis (NASH) has the potential to be a large and lucrative therapy market owing to the prevalence of the disease and the lack of approved agents. Patients with NASH are at…